Secondary hyperparathyroidism (SHPT) occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH. Parathyroid hormone controls the level of calcium is in blood and within bones.
Secondary hyperparathyroidism can cause bone disease. It can also cause calcium to build up in tissues and organs such as the heart and blood vessels. The bones are in a constant state of change. There are cells that build new bone and cells that remove old bone. This process is known as “bone turnover.” If one has secondary hyperparathyroidism, bone turnover is high. This means that the cells that remove bone are working more quickly than the cells that build new bone, causing your bones to become weak and brittle. This can increase your chances of having bone pain and fractures. For diagnosis of SHPT, Evaluation in SHPT consists of monitoring of lab values of PTH, calcium, phosphorus, vitamin D levels, and renal function.
Get FREE sample copy at:
The Secondary Hyperparathyroidism market report also covers emerging drugs, current treatment practices, Secondary Hyperparathyroidism market share of the individual therapies, current and forecasted Secondary Hyperparathyroidism Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Secondary Hyperparathyroidism treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Secondary Hyperparathyroidism Market Key Facts
As per the study conducted by Laura Cotoi et al. (2019), The prevalence in Europe of Secondary hyperparathyroidism among patients requiring renal replacement therapies is estimated at 43.8% in France, 46.8% in Russia, and 42.9% in the United Kingdom. United States has a prevalence of 54%.
As per the study titled “Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States” conducted by Sun Moon Kim et al. (2016), there was identified 32,971 parathyroidectomies for secondary hyperparathyroidism between 2002 and 2011. The overall rate of parathyroidectomy was approximately 5.4/1000 patients
Key Benefits of Secondary Hyperparathyroidism Market Report
Secondary Hyperparathyroidism market report provides an in-depth analysis of Secondary Hyperparathyroidism Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Secondary Hyperparathyroidism market report will help in developing business strategies by understanding the Secondary Hyperparathyroidism Market trends & developments, key players and future market competition that will shape and drive the Secondary Hyperparathyroidism market in the upcoming years.
The Secondary Hyperparathyroidism market report covers Secondary Hyperparathyroidism current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Secondary Hyperparathyroidism market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Secondary Hyperparathyroidism market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Secondary Hyperparathyroidism market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Secondary Hyperparathyroidism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Secondary Hyperparathyroidism Epidemiology
The Secondary Hyperparathyroidism epidemiology section covers insights about historical and current Secondary Hyperparathyroidism patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Secondary Hyperparathyroidism Drugs Uptake and Key Market Players
The Secondary Hyperparathyroidism Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Secondary Hyperparathyroidism market or expected to get launched in the market during the study period. The analysis covers Secondary Hyperparathyroidism market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The current pipeline for Secondary Hyperparathyroidism has many significant products. The dynamics of Secondary Hyperparathyroidism market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also due to the expected launch of many therapies during the forecast period.
Some of the key players in the Secondary Hyperparathyroidism market includes:
Sanwa Kagaku Kenkyusho
And many others.
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Secondary Hyperparathyroidism Competitive Intelligence Analysis
4. Secondary Hyperparathyroidism Market Overview at a Glance
5. Secondary Hyperparathyroidism Disease Background and Overview
6. Secondary Hyperparathyroidism Patient Journey
7. Secondary Hyperparathyroidism Epidemiology and Patient Population
8. Secondary Hyperparathyroidism Treatment Algorithm, Current Treatment, and Medical Practices
9. Secondary Hyperparathyroidism Unmet Needs
10. Key Endpoints of Secondary Hyperparathyroidism Treatment
11. Secondary Hyperparathyroidism Marketed Products
12. Secondary Hyperparathyroidism Emerging Therapies
13. Secondary Hyperparathyroidism Seven Major Market Analysis
14. Attribute Analysis
15. Secondary Hyperparathyroidism Market Outlook (7 major markets)
16. Secondary Hyperparathyroidism Access and Reimbursement Overview
17. KOL Views on the Secondary Hyperparathyroidism Market.
18. Secondary Hyperparathyroidism Market Drivers
19. Secondary Hyperparathyroidism Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Secondary Hyperparathyroidism Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Secondary Hyperparathyroidism in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Secondary Hyperparathyroidism Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Secondary Hyperparathyroidism market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States